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ABSTRACT 48 
T cells expressing CD19-specific chimeric antigen receptors (CARs) with 49 
endodomains that encode a signaling domain derived from CD3ζ and CD28 or 50 
41BB have potent antitumor activity in early phase clinical studies for B-cell 51 
malignancies. Besides CD19-specific CARs, other approaches are actively being 52 
pursued to redirect T cells to CD19, including recombinant bispecific T-cell 53 
engager (BiTE) proteins or T cells genetically modified to express BiTEs 54 
(engager [ENG] T cells). Since BiTEs provide no costimulation, we investigated 55 
here if provision of costimulation through CD28 and 41BB enhances the effector 56 
function of CD19-ENG T cells. CD19-ENG T cells expressing CD80 and 41BBL 57 
on their cell surface (CD19-ENG.41BBL/CD80 T cells) were generated by 58 
retroviral transduction. CD19-ENG.41BBL/CD80 T cells retained their antigen 59 
specificity and had superior effector function compared to both unmodified T cells 60 
and CD19-ENG T cells expressing either CD80, 41BBL or no costimulatory 61 
molecule, as judged by cytokine (IFN and IL2) production, T-cell proliferation, 62 
and their ability to sequentially kill target cells. In vivo, CD19-ENG.41BBL/CD80 63 
T cells had superior antileukemia activity in the BV173 xenograft model resulting 64 
in a survival advantage in comparison to CD19-ENG T cells. Thus, provision of 65 
costimulation is critical for the effector function of ENG T cells.  66 
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INTRODUCTION 68 
Hematological malignancies of B-cell origin are an important cause of cancer-69 
related mortality since the prognosis of relapsed or refractory disease remains 70 
poor (1-4). In recent years, immunotherapeutic approaches have shown promise 71 
in the treatment of CD19+ hematological malignancies, including the adoptive 72 
transfer of T cells expressing CD19-specific chimeric antigen receptors (CARs) 73 
or the infusion of bispecific antibodies (BiTEs) to redirect T cells to CD19+ tumor 74 
cells (5-16). 75 
 76 
Although CD19-targeting CAR T cells and BiTEs have been successful in clinical 77 
studies, however, both have been associated with toxicities including cytokine 78 
release syndrome (CRS) and neurotoxicity (7,10,11,14,17,18). Thus, exploration 79 
of alternative strategies to redirect the immune system towards CD19+ 80 
malignancies are needed. For example, T cells, genetically modified to secrete 81 
CD19-specific BiTEs (CD19-ENG T cells), kill not only CD19+ cells, but also 82 
recruit bystander T cells to tumor cells in an antigen specific manner (19,20). 83 
Although CD19-ENG T cells had antitumor activity in preclinical animal models, 84 
consistent IL2 production and T-cell expansion in vivo was dependent on the 85 
presence of costimulatory molecules on the cell surface of tumor cells (19). 86 
 87 
Because most CD19+ malignancies do not express costimulatory molecules on 88 
their cell surface (19), we explored here if expressing the costimulatory 89 
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molecules CD80 and/or 41BBL on the cell surface of CD19-ENG T cells 90 
enhanced their effector function. Our results indicate that costimulation with 91 
CD80 and 41BBL is required for optimal antigen-dependent CD19-ENG T-cell 92 
activation.   93 
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MATERIALS AND METHODS 94 
Cell lines and culture conditions 95 
The Ph-positive chronic B lymphoblastic leukemia (ALL) cell line BV173 (German 96 
Collection of Microoganisms and Cell Cultures (DSMZ), Braunschweig, 97 
Germany), and the ALL cell line Nalm 6 (DSMZ) were used as CD19+ targets. 98 
The generation of firefly luciferase (ffLuc)-expressing BV173 (BV173.ffLuc) were 99 
described previously (21,22). K562 (chronic myelogenous leukemia; ATCC, 100 
Manassas, VA), and KG1a (acute myelogenous leukemia; ATCC) were used as 101 
negative controls.  All cell lines were grown in RPMI 1640 (Thermo Scientific, 102 
Waltham, MA) except for KG1a (IMDM; Thermo Scientific).  293T cells (ATCC) 103 
were used for packaging retroviral vectors and grown in DMEM. All media was 104 
supplemented with 10-20% FBS (Thermo Scientific) and GlutaMAX-I (2 mmol/L; 105 
Invitrogen, Carlsbad, CA), and all cell lines were grown in standard (37°C, 5% 106 
CO2) tissue culture incubators. 107 
Cell lines were purchased between 2012 and 2016. The Characterized Cell Line 108 
Core Facility at MD Anderson Cancer Center, Houston, Texas, performed cell 109 
line validation. Once thawed, cell lines were kept in culture for a maximum of 110 
three months before a new reference vial was thawed. All cell lines were tested 111 
on a regular basis for mycoplasma and were negative. 112 
 113 
Generation of retroviral vectors  114 
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The generation of SFG retroviral vectors encoding the CD19- or EphA2-ENG 115 
molecule and mOrange were previously described (19,23). MSCV retroviral 116 
vectors encoding CD80, 41BBL, or 41BBL and CD80 were generated by 117 
subcloning CD80 from pORF.CD80 (Invivogen, San Diego, CA, USA), and/or 118 
41BBL from pORF.41BBL (Invivogen) into MSCV-I-GFP(M) (provided by the late 119 
Elio Vanin, Northwestern University Feinberg School of Medicine, Chicago, IL). 120 
RD114-pseudotyped retroviral particles were generated as previously described 121 
(24).  122 
 123 
Generation of engager T cells 124 
All methods involving human subjects were carried out in accordance to the 125 
Declaration of Helsinki. Human peripheral blood mononuclear cells (PBMCs) 126 
from healthy donors were obtained under a Baylor College of Medicine IRB 127 
approved protocol, after acquiring informed consent. Retroviral transduction was 128 
done as previously described (25,26). PBMCs were stimulated on OKT3 (1µg/mL; 129 
CRL-8001, ATCC) and CD28 (1µg/mL; BD Bioscience) antibody-coated, non-130 
tissue culture treated 24-well plates. Human interleukin 7 (IL7; 10ng/mL; 131 
Peprotech, Rocky Hill, NJ) and human interleukin 15 (IL15; 5ng/mL; Peprotech, 132 
Rocky Hill, NJ) were added to cultures on day 2. On day 3, T cells were 133 
transduced with retroviral particles on RetroNectin-coated plates (Takara Bio 134 
USA, Mountainview CA) in the presence IL7 (10ng/mL) and IL15 (5 ng/mL). T 135 
cells were subsequently expanded with IL7 and IL15. Non-transduced (NT) T 136 
cells were activated with OKT3/CD28 and expanded in parallel with IL7 and IL15. 137 
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Cells were cultured for 7-10 days prior to being used for in vitro or in vivo 138 
experiments. 139 
 140 
Flow cytometric analysis  141 
Monoclonal antibodies (mAb) for the following markers were used for 142 
fluorescence activated cell sorting (FACS) analysis as described elsewhere (26): 143 
41BBL (Clone C65-485; BD Biosciences, San Jose, CA) conjugated with GAM-144 
APC antibody (BD Biosciences; cat. 550826), CD80-PerCP (eBioscience, San 145 
Diego, CA; cat. 46080942); CD3-APC (clone HIT3a; cat. 555342), CD4-PECy7 146 
(clone SK3; cat. 560909), CD8-APCH7 (clone SK1; cat. 560179), CCR7-FITC 147 
(clone 150503; cat. 561271), CD62L-APC (clone DREG-56; cat. 559772), CD95-148 
Pacific Blue (clone DX2; cat. 562616), and CD45RO-PercP (clone UCHL1; cat. 149 
560607) (all BD Biosciences, Mountain View, CA). Isotype controls used were 150 
IgG1-FITC, IgG1 APC, IgG1Pe.Cy7, IgG1APC H7, IgG1 Pac Blue and IgG1 151 
PercP.Cy7 (all from BD Biosciences). 10,000 cells (non-transduced [NT] or 152 
genetically modified) per sample were analyzed by a FACSCalibur instrument 153 
(BD Biosciences) using Cell Quest Software (BD Biosciences) and a BD Canto II 154 
instrument (BD Biosciences) using FACSDiva software (BD Biosciences) and 155 
analyzed using Kaluza Analysis 1.3 (Beckman Coulter) and FlowJo v10 (FlowJo 156 
LLC).  157 
 158 
Coculture assays and ELISA 159 
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NT or genetically modified effector T cells were plated at a 2:1 effector to target 160 
(E:T) ratio with CD19+ (BV173) or CD19– (K562) target cells. Coculture 161 
supernatants were collected after 48 hours, snap frozen, and stored for cytokine 162 
analysis at a later time. IFN and IL2 concentrations were determined using 163 
ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer’s 164 
instructions.  165 
 166 
Cytotoxicity assay 167 
Cytotoxic activity of ENG T cells against targets was determined by standard 168 
51Chromium (Cr) release assay. 1x106 target cells were labeled with 50Ci 51Cr 169 
and incubated for 1 hour. Targets were then washed and 5x103 cells were 170 
cocultured with effector T cells at different effector to target (E:T) ratios. 171 
Supernatants were analyzed for radioactivity using a Wizard gamma counter 172 
Model 2470 (Perkin Elmer, Shelton CT) reader after 4 hour incubation. Percent 173 
lysis was calculated as previously described (21).  174 
 175 
Sequential killing assay 176 
To determine the cytolytic activity of T cells after repeat stimulations, we 177 
performed a sequential killing assay with GFP-positive tumor cell lines (BV173 178 
and Nalm 6) as outlined in Supplementary Fig. S4.  1.5x105 GFP-positive tumor 179 
cells were plated at different E:T ratios (1:4 and 1:8) with T cells in a 48-well 180 
plate.  Every 3 to 4 days, cells were mixed in the well, and a small aliquot of cells 181 
was removed for analysis. The remaining cells were washed once, resuspended 182 
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in fresh, cytokine-free RPMI and 1.5x105 fresh tumor cells were added. Cells 183 
were stained with 7-AAD (BD Biosciences; cat. 559925) and anti-CD3-APC (BD 184 
Biosciences) before enumerating viable GFP+ (tumor) and CD3+ T cells by FACS 185 
analysis using Countbright Absolute Counting Beads (Life technologies, Eugene, 186 
OR). Coculture assays were also performed in a 24-well plate format in which 187 
tumor cells and T cells were plated at a 1:1 E:T ratio (5x105 cells each per well). 188 
After 5 days, cells were mixed in the well, and a small aliquot of cells was 189 
removed for analysis. The remaining cells were washed once, resuspended in 190 
fresh, cytokine-free RPMI and 5x105 fresh tumor cells were added.  191 
 192 
 193 
In vivo experiments 194 
Animal experiments were performed on a protocol approved by the Baylor 195 
College of Medicine Institutional Animal Care and Use Committee in accordance 196 
to the American Association for Laboratory Animal Science. Eight to 10-week old 197 
NSG mice (NOD.Cg-Prkdcscid/Il2rgtm1Wjl/SzJ; JAX Mice, Bar Harbor, ME) were 198 
sublethally irradiated with 120 cGy 24 hours before the intravenous (i.v.) injection 199 
of 3x106 BV173.ffLuc cells. Mice were treated with 1x106 CD19-ENG, CD19-200 
ENG.CD80.41BBL or EphA2-ENG.CD80/41BBL T cells given i.v. on day 7 after 201 
tumor cell injection. The same model was used to track T cells in vivo, but in this 202 
case, unmodified BV173 cells and T cells genetically modified to express an 203 
enhanced green fluorescent protein ffLuc fusion gene (eGFP.ffLuc) were 204 
injected. Mice were imaged using the IVIS® system (IVIS, Xenogen Corp., 205 
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Alameda, CA) as previously described (21), and euthanized at predefined 206 
endpoints (antitumor activity: day 80; T-cell persistence: day 100) or when they 207 
met euthanasia criteria in accordance with the Center for Comparative Medicine 208 
at Baylor College of Medicine.   209 
 210 
Statistical analysis 211 
Data were summarized using descriptive statistics. Comparisons of continuous 212 
variables among three or more groups were made by one-way ANOVA, while 213 
comparisons between two groups were made by t-test or Wilcoxon rank-sum test 214 
when appropriate. Multiple comparisons were adjusted by the Holm’s method.  215 
Survival times from tumor cell injection in the mouse experiments were analyzed 216 
by the Kaplan–Meier method and the Gehan-Wilcoxon test. GraphPad Prism 5 217 
software (GraphPad software, Inc., La Jolla, CA), SAS 9.4, and R 3.3.2 were 218 
used for statistical analysis. P values < 0.05 were considered statistically 219 
significant. 220 
  221 
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RESULTS  222 
Generation and characterization of CD19-ENG T cells 223 
We generated T cells expressing CD19-ENG, CD19-ENG and CD80 (CD19-224 
ENG.CD80), CD19-ENG and 41BBL (CD19-ENG.41BBL), and CD19-ENG with 225 
both 41BBL and CD80 (CD19-ENG.41BBL/CD80) by transducing CD3/CD28-226 
activated T cells with one or two retroviral vectors encoding the respective 227 
transgenes (Fig. 1A). Five to seven days post transduction, genetically modified 228 
T cells were enumerated by FACS analysis for mOrange (CD19-ENG), CD80, 229 
and 41BBL expression (Fig. 1B,C). Mean mOrange expression ranged from 230 
53.9% (±6.2%) to 79% (±3%) with no significant differences between transduced 231 
T-cell populations. CD19-ENG.CD80 (mean 55.9% ±4.4%) and CD19-232 
ENG.41BBL/CD80 (mean 53.6% ±13%) T cells showed significantly higher 233 
expression of CD80 molecules when compared to CD19-ENG (p=0.0002 and 234 
p=0.004) and CD19-ENG.41BBL T cells (p=0.0002 and p=0.003). CD19-235 
ENG.41BBL (mean 62.8% ±14%) and CD19-ENG.41BBL/ CD80 T cells (mean 236 
86.7% ±8%) expressed significantly more 41BBL than CD19-ENG and CD19-237 
ENG.CD80 T cells (p=0.004 and p=0.0002, respectively). These results indicate 238 
the successful generation of CD19-ENG T cells coexpressing CD80 and/or 239 
41BBL.  240 
 241 
Ten to 14 days post transduction, CD19-ENG T-cell populations were stained for 242 
CD3, CD4, CD8, CD45RO, CCR7, TIM3, LAG3, and PD-1 to determine if 243 
expression of costimulatory molecules changes their phenotype. The ratio of 244 
CD8+ to CD4+ T cells was 3 to 1 for T cells expressing CD19-ENG, and T cells 245 
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had predominantly an effector memory RA (EMRA; CD45RO– CCR7–) phenotype 246 
(Fig. 2A,B; gating strategy in Supplementary Fig. S1B). Expressing CD80 247 
and/or 41BBL on CD19-ENG T cells changed neither CD8:CD4 T-cell ratio nor 248 
phenotype. Non-transduced (NT) T cells had a similar CD8:CD4 ratio, but had a 249 
predominately naïve (N; CD45RO– CCR7+) and central memory (CM; CD45RO+ 250 
CCR7+) phenotype (Fig. 2A,B). PD-1 and LAG3 expression in T cells transduced 251 
with CD19-ENG, CD19-ENG.CD80, CD19-ENG.41BBL, or CD19-252 
ENG.41BBL.CD80 was not significantly different from NT T cells, and no T-cell 253 
population expressed TIM3 (Fig. 2C,D; gating strategy in Supplementary Fig. 254 
S1C). Thus, expression of CD80 and/or 41BBL on the cell surface of CD19-ENG 255 
T cells does not change their phenotype. To further investigate the naïve cell 256 
population of NT T cells, we performed staining for CD62L and CD95, 257 
demonstrating a high percentage of T cells with a stem cell memory-like 258 
phenotype (CD45RO– CCR7+ CD62L+ CD95+ cells; Supplementary Fig. S2), 259 
which is consistent with previous findings by others (27-29). 260 
 261 
 262 
CD80 and 41BBL enhance antigen-dependent IFNγ and IL2 production 263 
To evaluate if expressing CD80 and/or 41BBL on the cell surface of CD19-ENG 264 
T cells enhanced their effector function, we performed cytotoxicity assays and 265 
determined the production of IFNγ and IL2 after exposure to CD19+ target cells. 266 
CD19-ENG T cells killed CD19+ (BV173) but not CD19– (KG1a) tumor cells, and 267 
expression of CD80 and/or 41BBL did not change their specificity or cytolytic 268 
on August 20, 2017. © 2017 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 18, 2017; DOI: 10.1158/2326-6066.CIR-17-0171 
14 
 
activity (Fig. 3A). This was confirmed for a second CD19+ target cell (Nalm 6; 269 
Supplementary Fig. S3). To confirm that expression of CD80 and 41BBL did not 270 
result in nonspecific target cell killing, we expressed both molecules in T cells 271 
transduced with an ENG molecule specific for an irrelevant antigen (EphA2-272 
ENG). EphA2-ENG.41BBL/CD80 T cells did not kill BV173 or KG1a (Fig. 3A).  273 
 274 
To determine IFNγ and IL2 production after antigen exposure, CD19-ENG, 275 
CD19-ENG.CD80, CD19-ENG.41BBL, CD19-ENG.41BBL/CD80, or EphA2-276 
ENG.41BBL/CD80 T cells were cultured with CD19+ (BV173) or CD19– (K562) 277 
cell lines, two cell lines that do not express the costimulatory molecules CD80, 278 
CD86, or 41BBL (19).  After 24 hours, the concentration of IFNγ and IL2 in 279 
culture media was determined by ELISA. CD19-ENG.41BBL/CD80 T cells 280 
secreted significantly more IFNγ (p=0.037) and IL2 (p=0.011) in comparison to 281 
CD19-ENG T cells (Fig. 3B).  Although CD19-ENG.CD80 and CD19-282 
ENG.41BBL T cells also secreted more IFNγ and IL2 than CD19-ENG T cells, 283 
this difference did not reach significance. EphA2-ENG.41BBL/CD80 T cells did 284 
not produce significant levels of IFNγ and IL2 in the presence of CD19+ or CD19–285 
targets, confirming antigen specificity (Fig. 3B).  Thus, expression of CD80 and 286 
41BBL on the cell surface of CD19-ENG T cells is required to significantly 287 
enhance their ability to secrete IFNγ and IL2 after antigen-specific T-cell 288 
activation. 289 
 290 
 291 
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CD80 and 41BBL enhance sequential antitumor activity 292 
To evaluate if provision of costimulation enhanced the sequential killing capability 293 
of CD19-ENG T cells, we performed a sequential killing assay (outlined in 294 
Supplementary Fig. S4). BV173 or Nalm 6 cells were cocultured with different 295 
CD19-ENG T cell populations at an initial E:T ratio of 1:4 or 1:8. Every 3 to 4 296 
days, T cells and tumor cells were enumerated before washing cells, 297 
resuspending in cytokine-free media, and adding fresh tumor cells. For BV173 at 298 
both E:T ratios and for Nalm 6 at an E:T ratio of 1:4, CD19-ENG.41BBL/CD80 T 299 
cells killed target cells up to the 7th time fresh tumor cells were added. CD19-300 
ENG.CD80 T cells killed target cells up to the 5th, CD19-ENG.41BBL T cells up to 301 
the 4th, and CD19-ENG T cells up to the 2nd time, respectively (Fig. 4A-C; 302 
Supplementary Fig. S5A). For Nalm 6, at an initial E:T ratio of 1:8, CD19-303 
ENG.41BBL.CD80 T cells could kill targets for up to the 4th time fresh tumor cells 304 
were added, with other CD19-ENG T cell populations being able to kill up to the 305 
3rd time (Supplementary Fig. S5B). CD19-ENG.41BBL/CD80 T cells had the 306 
most consistent antitumor activity against both targets at both E:T ratios in 307 
comparison to  CD19-ENG T cells (Fig. 5B). CD19-ENG.41BBL/CD80 T cells 308 
were also the only population that expanded significantly more than CD19-ENG 309 
in the presence of both targets and E:T ratios (Fig. 5A,B). Thus, our analysis 310 
demonstrated the following T-cell effector rank order: CD19-ENG.41BBL/CD80 > 311 
CD19-ENG.CD80 = CD19-ENG.41BBL > CD19-ENG T cells (Fig. 5). Due to the 312 
superior effector function of CD19-ENG.41BBL.CD80 T cells in all performed in 313 
vitro assays, we selected these cells for our in vivo experiments. Improved 314 
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cytolytic activity of CD19-ENG.41BBL/CD80 and CD19-ENG.CD80 T cells was 315 
also confirmed in a coculture assay in which T cells were re-exposed to tumor 316 
cells every 5 days (Supplementary Fig. S6). Although CD19-ENG.41BBL/CD80 317 
T cells were effective against both targets, T-cell expansion was limited in the 318 
presence of Nalm 6 cells. We, therefore, investigated whether a difference in PD-319 
L1 expression existed between BV173 and Nalm 6 cells. At baseline, neither cell 320 
line expressed PD-L1, whereas IFNγ exposure induced PD-L1 expression in 321 
Nalm 6 cells but not in BV173 cells (Supplementary Fig. S7). 322 
 323 
CD19-ENG.41BBL/CD80 T cells have superior antitumor activity in vivo  324 
To evaluate the antitumor activity of CD19-ENG.41BBL/CD80 T cells, NSG mice 325 
were injected with 3x106 BV173.ffLuc cells, and on day 7 received a single i.v. 326 
dose of 1x106 CD19-ENG, CD19-ENG.41BBL/CD80, or EphA2-327 
ENG.41BBL/CD80 T cells. Whereas CD19-ENG T cells had no antitumor activity 328 
at a cell dose of 1x106 as previously reported (19), 1x106 CD19-329 
ENG.41BBL/CD80 T cells had potent antitumor activity in 9/10 mice as judged by 330 
bioluminescence imaging (Fig. 6A,B). Long-term follow up to 80 days revealed 331 
no weight loss or leukemia recurrence, resulting in a significant survival 332 
advantage of CD19-ENG.41BBL/CD80 T cell treated mice (p<0.0001; Fig. 6C,D). 333 
EphA2-ENG.41BBL/CD80 T cells had no antitumor activity. 334 
 335 
CD19-ENG T cells do not expand in the BV173 leukemia model in vivo.(19) To 336 
evaluate if CD19-ENG.41BBL/CD80 T cells expand in vivo in an antigen-337 
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dependent manner, NSG mice were injected with 1x106 BV173 cells, and on day 338 
7 received a single i.v. dose of 1x106 CD19-ENG.41BBL/CD80 or EphA2-339 
ENG.41BBL/CD80 T cells, that were also genetically modified to express 340 
eGFP.ffLuc. Control mice that did not receive any tumor were injected with 341 
eGFP.ffLuc-expressing CD19-ENG.41BBL/CD80 T cells. Within the first 5 days 342 
post T-cell injection, CD19-ENG.41BBL/CD80 T cells expanded significantly in 343 
the femurs of tumor-bearing mice, as judged by bioluminescence imaging, in 344 
contrast to mice without tumors (Fig. 7A, B). EphA2-ENG.41BBL/CD80 T cells 345 
expanded much more slowly than CD19-ENG.41BBL/CD80 in tumor-bearing 346 
mice, demonstrating that the early expansion of CD19-ENG.41BBL/CD80 T cells 347 
post injection is antigen-specific. Starting 7 days post injection, no statistical 348 
significant difference in the bioluminescence signal among all three groups was 349 
seen. Long-term follow-up revealed that all three T-cell populations expanded 350 
until day 13. Afterwards, T cells in the CD19-ENG.41BBL/CD80 T cells +/- tumor 351 
groups contracted and persisted in low numbers until the end of the end of the 352 
experiment (day 93 post T-cell injection) with no evident weight loss 353 
(Supplementary Fig. S8A-C). Area under the curve analysis revealed a 354 
significantly greater (p<0.01) expansion and persistence of CD19-355 
ENG.41BBL/CD80 T cells in the presence of tumor cells (Supplementary Fig. 356 
S8B). Tumor-bearing mice that had received EphA2-ENG.41BBL/CD80 T cells 357 
needed to be euthanized on day 13, which is consistent with tumor progression 358 
(Fig. 6). 359 
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 361 
DISCUSSION 362 
In this manuscript, we demonstrate that the expression of CD80 and 41BBL on 363 
the cell surface of CD19-ENG T cells enhances their effector function. 364 
Expression of CD80 and 41BBL had no impact on antigen specificity, but 365 
improved antigen-dependent cytokine secretion (IFNγ and IL2), T-cell expansion, 366 
and antitumor activity of CD19-ENG T cells. 367 
 368 
Optimal T-cell activation requires antigen-specific CD3ζ stimulation (signal 1) and 369 
costimulation (signal 2). Upon proper costimulation, T cells produce cytokines or 370 
induce cytokine production by neighboring cells (signal 3), which is critical for 371 
their expansion (30-33). Comparisons of the effector function of T cells that 372 
express 1st generation CARs, containing only a CD3ζ endodomain, to 2nd 373 
generation CARs, whose endodomains contain the CD3ζ signaling domain plus 374 
those from costimulatory molecules such as CD28, 41BB, OX40, or CD27, has 375 
highlighted the need of costimulation for proper T cell activation (34-36). Whether 376 
T cells expressing a CAR that encodes two costimulatory endodomains  (3rd 377 
generation CAR) have superior effector function than 2nd generation CAR T cells 378 
remains controversial and depends on the used tumor model (37-39).  379 
 380 
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Besides incorporating costimulatory signaling domains into CARs, investigators 381 
have also explored the expression of costimulatory molecules on the cell surface 382 
of CAR T cells (40). A study by Zhao and colleagues suggests that T cells 383 
expressing CAR.CD28.ζ and 41BBL have superior effector function in 384 
comparison to T cells expressing CAR.ζ, CD80 and 41BBL, or 385 
CAR.41BB.CD28.ζ on their cell surface (41). Here, we explored if provision of 386 
costimulatory molecules improved the effector function of CD19-ENG T cells, 387 
which secrete BiTEs that only activate CD3ζ. We successfully generated CD19-388 
ENG T cells expressing CD80 and/or 41BBL. Expression of both molecules did 389 
not change the phenotype of CD19-ENG T cells and did not result in upregulation 390 
of exhaustion markers (PD-1, LAG3, TIM3), which has been observed in T cells 391 
that express CARs that are constitutively active (tonic signaling) (42). However, 392 
expressing CD19-ENG in T cells led to a decrease of naïve (CD45RO– CCR7+) T 393 
cells in comparison to NT T cells, which might reflect the presence of residual B-394 
cells in our culture system at the time of transduction, resulting in T-cell activation 395 
through CD19-ENGs. Although CD19-ENG T cells did not produce significant 396 
amounts of IFNγ in the absence of CD19+ target cells, baseline tonic signaling by 397 
CD19-ENG bound to the T-cell surface cannot be excluded as another 398 
mechanism for a decrease of naïve T cells. Further studies are needed to 399 
investigate the mechanism of these phenotypic changes including molecular and 400 
epigenetic studies (43,44). 401 
 402 
on August 20, 2017. © 2017 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 18, 2017; DOI: 10.1158/2326-6066.CIR-17-0171 
20 
 
Expression of both CD80 and 41BBL was necessary for a significant increase in 403 
antigen-dependent IL2 production in comparison to CD19-ENG T cells. This 404 
differs from CARs in which a single costimulatory endodomain is sufficient 405 
(45,46). However, it is consistent with findings by others that expression of CD80 406 
and 41BBL is required on the cell surface of CAR.ζ T cells for significant antigen-407 
dependent IL2 production (40,41). Expression of both CD80 and 41BBL was also 408 
required for optimal cytolytic activity and expansion of CD19-ENG T cells in the 409 
sequential killing assays we performed. In these assays, CD19-ENG T cells 410 
expressing either CD80, 41BBL or no costimulatory molecule were re-exposed to 411 
tumor cells every 3 to 4 days to mimic the in vivo situation in which tumor cells 412 
are exposed to tumor cells constantly when they first arrive at tumor sites. All 413 
CD19-ENG T-cell populations expanded better in the presence of BV173 than 414 
Nalm 6, most likely due to the upregulation of PD-L1 on Nalm 6 cells in the 415 
presence of IFNγ. Here we explored only one combination of costimulatory 416 
molecules. In the setting of CAR.ζ T cells, investigators have compared the 417 
benefits of expressing CD80 with several members of the tumor necrosis factor 418 
ligand family, including 41BBL, CD70, OX40L, and CD30L (40). Their results 419 
indicate that combining CD80 and 41BBL costimulation is most effective in 420 
enhancing the effector function of CAR.ζ T cells (40). 421 
 422 
In vivo, expression of CD80 and 41BBL on the cell surface of CD19-ENG T cells 423 
resulted in a significant increase in their antitumor activity, confirming the in vitro 424 
sequential killing assay result. This result was not due to nonspecific tumor killing 425 
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because control EphA2-ENG.41BBL/CD80 T cells had no antitumor activity. 426 
CD19-ENG.41BBL/CD80 T cells did not induce significant xenogenic graft versus 427 
host disease (GvHD), as judged by weight and/or fur loss, during the 80-day 428 
observation period post T-cell injection nor was it observed in the T-cell 429 
persistence experiment with a follow-up of 93 days post T-cell injection. Future 430 
studies are planned to confirm our findings by performing a detailed histological 431 
analysis of organs of euthanized mice.  432 
 433 
Besides expressing costimulatory molecules on the cell surface of ENG T cells, 434 
other strategies could be explored to provide costimulation. For example, others 435 
have generated fusion proteins that consist of a tumor-associated antigen (TAA)-436 
specific scFv and the ectodomain (ECD) of CD80 or 41BBL (32,33). T cells 437 
incubated with BiTEs, TAA.scFv-CD80.ECD, and TAA.scFv-41BBL.ECD 438 
recombinant proteins result in improved IFNγ production and T-cell proliferation 439 
in comparison to T cells that were incubated with BiTEs and TAA.scFv-440 
CD80.ECD (33,47). These results mirror our findings that provision of two 441 
costimulatory signals results in enhanced effector function after BiTE-mediated 442 
T-cell activation.  443 
 444 
In summary, our study demonstrates that provision of CD80 and 41BBL 445 
enhances the effector function of CD19-ENG T cells. Our results are informative 446 
not only for the future clinical development of ENG T cells for hematological and 447 
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solid malignancies, but also for immunotherapeutic approaches that rely on the 448 
infusion of recombinant BiTE proteins or oncolytic viruses that are genetically 449 
engineered to produce BiTEs.  450 
 451 
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Figure Legends 622 
 623 
Figure 1: Generation of CD19-ENG T cells expressing CD80 and/or 41BB. 624 
(A) Scheme of retroviral constructs. (B) Representative dot plots for CD19-ENG 625 
(mOrange), CD80 (PercP) and 41BBL (APC) 5 to 7 days post transduction of 626 
CD3/CD28-activated T cells with retroviral vectors. (C) Mean and SD of 627 
mOrange, CD80, and 41BBL expression (n=3; * p<0.05 compared to CD19-ENG 628 
T cells, two-tailed t-test). 629 
 630 
Figure 2: Immunophenotype and exhaustion marker expression in CD19 631 
ENG T cells. 10 to 14 days post transduction, flow cytometric analysis was used 632 
to determine (A) Frequency of CD8+ and CD4+ T cells subsets (n=3, non-633 
significant (NS), one-way ANOVA); (B) Frequency of naïve (CD45RO– CCR7+), 634 
effector memory (CD45RO+ CCR7–), central memory (CD45RO+ CCR7+), and 635 
EMRA (CD45RO– CCR7–) T cells (n=6; naïve and EMRA T cells: NT vs CD19-636 
ENG +/- costimulatory molecules: p≤0.001, one-way ANOVA); Frequency of 637 
Tim3, PD-1, and LAG3 expression on (C) CD4+ cells and (D) CD8+ cells (n=3, 638 
NS, one-way ANOVA). 639 
 640 
Figure 3: Antigen specificity and cytokine secretion by CD19-ENG T cells. 641 
(A) Cytotoxicity assays were performed using CD19-ENG, CD19-ENG.CD80, 642 
CD19-ENG.41BBL, CD19-ENG.41BBL/CD80 and EphA2-ENG, 41BBL/CD80 T 643 
cells as effectors and CD19+ (BV173) and CD19– (KG1a) tumor cells as targets 644 
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at a E:T ratio of 10:1. Percent lysis is plotted using Tukey box and whisker plots. 645 
(n=4; assay performed in triplicates). (B) Effector T cells were cocultured with 646 
CD19+ (BV173), CD19– (KG1a) tumor cells, or media only at a ratio of 2:1. After 647 
48 hours, IFNγ and IL2 production was determined by ELISA and plotted using 648 
Tukey box and whisker plots (n=5; assay performed in duplicates, significance at 649 
p<0.05; one-way ANOVA).  650 
 651 
Figure 4: CD19-ENG.41BBL/CD80 T cells have improved ability to 652 
sequentially kill CD19+ target cells.  Sequential killing assays were performed 653 
as outlined in the material and methods section and Supplementary Fig S2. 654 
Absolute cell count of live tumor cells was obtained by flow cytometry using 655 
Countbright counting beads. (A,B) Live tumor cell number was plotted relative to 656 
tumor cell number at the start of each stimulation; (A) BV173 (n=3), (B) Nalm6 657 
(n=4). (C) Summary data presented as a heatmap denoting no antitumor activity 658 
for all donors (yellow), donor-dependent antitumor activity (blue/yellow), or 659 
antitumor activity in all donors (blue). Numbers 1-7 under cell line names denote 660 
stimulation number.  White boxes represent values not determined.  The 661 
Wilcoxon rank sum test was used to determine significance (p<0.05). 662 
 663 
Figure 5: CD19-ENG.41BBL/CD80 T cells have improved antigen-dependent 664 
proliferative capacity. (A) Sequential killing assays were performed as outlined 665 
in the material and methods section and Supplementary Fig S2. Absolute cell 666 
count of live T cells was obtained by flow cytometry using Countbright counting 667 
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beads. Fold T-cell expansion at each sequential stimulation is plotted. (B) 668 
Proliferation comparison table. Statistical significance was determined using the 669 
Wilcoxon rank sum test. Orange boxes denote comparison of T-cell numbers 670 
(dark orange: p <0.05, light orange p=NS). Blue boxes denote comparison of 671 
tumor cell numbers between different conditions (dark blue: p<0.05, light blue 672 
p=NS). 673 
 674 
Figure 6: CD19-ENG.41BBL/CD80 T cells have improved antitumor activity 675 
when compared to CD19 ENG T cells in vivo. NSG mice were sublethally 676 
irradiated and injected i.v. with BV173.ffLuc. On day 7, mice received one i.v. 677 
dose of 1x106 CD19-ENG (n=5), CD19-ENG.41BBL/CD80 (n=9), or EphA2-678 
ENG.41BBL/CD80 (n=5) T cells. Tumor growth was monitored by 679 
bioluminescence imaging. (A) Images of representative animals. (B) 680 
Bioluminescence signal (radiance = photons/sec/cm2/ sr) over time is plotted. (C) 681 
Shown are weights of animals over the course of the experiment. (D) Kaplan-682 
Meier survival curves for injected mice. Statistical significance was determined 683 
using the Wilcoxon rank sum test (p<0.0001). 684 
 685 
Figure 7: CD19 ENG.41BBL/CD80 T cells expand in vivo. NSG mice were 686 
sublethally irradiated and injected i.v. with BV173. On day 7, mice received one 687 
i.v. dose of 1x106 CD19-ENG.41BBL/CD80 (n=5) or EphA2-ENG.41BBL/CD80 688 
(n=4) T cells that were genetically modified with eGFP.ffLuc. Mice without tumors 689 
received one i.v. dose of 1x106 CD19-ENG.41BBL/CD80 (n=5). (A) Images of 690 
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representative animals over time are shown. (B) Plots of bioluminescence signal 691 
(radiance = photons/sec/cm2/sr) of femurs (*p<0.05 for day 1, ***p<0.001 for 692 
days 3 and 5, p=ns for day 7, by Gehan-Wilcoxon test). 693 
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